About Biocerna
Biocerna is a Healthcare company based in United States founded in 2012 by Christopher Sanders, and was acquired by Matrix Medical Network in October 2020. Non-invasive qPCR diagnostics for BCR-ABL translocations in CML are provided. The company has 14 employees. Its chief executive, as recorded, is Christopher Sanders. Its focus areas include Life Sciences, Clinical Genomics, Amplification Based and PCR. Its legal entity is BIOCERNA LLC. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
Biocerna was founded in 2012 in Howard County, United States, within the biotechnology sector. A non-invasive diagnostics platform based on quantitative real-time PCR technology is developed for detecting major and minor BCR-ABL gene translocations. Operations focus on monitoring chronic myeloid leukemia through products such as the QuantideX qPCR BCR-ABL IS kit for p210 translocations and the QuantideX qPCR BCR-ABL minor kit for e1a2 fusion transcripts.
- Headquarters Howard County, United States
- Employees 14
- Founders Christopher Sanders
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website biocerna.com
- Social LinkedIn
- Acquired by Matrix Medical Network (Oct 2020)
- Legal Name Biocerna Llc
- Investors
- Employee Count14
- Acquired byMatrix Medical Network
(Oct 2020)
Investors in Biocerna
Biocerna has secured backing from 1 investor. Prominent investors backing the company include Matrix Medical Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Data analytics and managed services are provided for healthcare sectors. | 2001 | matrixmedicalnetwork.com | Scottsdale, United States |
Investor details for Biocerna
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biocerna
1 people are tracked at Biocerna (1 in leadership); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Christopher Sanders | Founder & CEO | Leadership |
Complete people profiles for Biocerna
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biocerna
2 dated milestones of Biocerna across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Biocerna is founded.
- Exit Acquired by Matrix Medical Network.
Competitors of Biocerna
Biocerna has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of Biocerna
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Biocerna (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biocerna
Complete news archive for Biocerna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biocerna
Biocerna was founded in 2012.
Biocerna is headquartered in United States. It is registered at Maryland, United States.
Christopher Sanders is the CEO of Biocerna, as recorded in our data. They have also founded this company.
Biocerna has 14 employees.
Biocerna was founded in 2012 in Howard County, United States, within the biotechnology sector. A non-invasive diagnostics platform based on quantitative real-time PCR technology is developed for detecting major and minor BCR-ABL gene translocations. Operations focus on monitoring chronic myeloid leukemia through products such as the QuantideX qPCR BCR-ABL IS kit for p210 translocations and the QuantideX qPCR BCR-ABL minor kit for e1a2 fusion transcripts.
Biocerna's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
Biocerna has 1 investor. Key investors include Matrix Medical Network.
Biocerna operates through Biocerna Llc.
Yes. Biocerna was acquired by Matrix Medical Network in October 2020.